Jazz Pharmaceuticals plc — Director's Dealing 2022

Mar 9, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2022-03-03

Reporting Person: Iannone Robert (EVP, Global Head of R&D and Ch)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-03	Ordinary Shares	A	11374	$0.0	Acquired	40584	Direct
2022-03-05	Ordinary Shares	F	1327	$153.96	Disposed	39257	Direct

Footnotes

F1: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2022, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.

F2: Includes 124 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2021.

F3: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.